'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
CONCLUSION: Overall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use.PMID:38514505 | DOI:10.1007/s12325-024-02809-w (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Norman Gaylis Charlotte Both Lena Lemke Oliver von Richter Paul Yamauchi Source Type: research
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis
CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3 (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Thais Montezuma Livia Fernandes Probst Matheus Oliveira Almeida Source Type: research
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
CONCLUSION: Overall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use.PMID:38514505 | DOI:10.1007/s12325-024-02809-w (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Norman Gaylis Charlotte Both Lena Lemke Oliver von Richter Paul Yamauchi Source Type: research
Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year
CONCLUSIONS: Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.PMID:38513258 | DOI:10.1080/09546634.2024.2331782 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 21, 2024 Category: Dermatology Authors: Yizhang Liu Kun Hu Lu Jian Yongfang Duan Mi Zhang Yehong Kuang Source Type: research
‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
ConclusionOverall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use. (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research
Case report: A case of resistant anti ‐SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 20, 2024 Category: Rheumatology Authors: Maria Farhat,
Boutros Soutou Tags: LETTER TO THE EDITOR Source Type: research
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
CONCLUSION: The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.PMID:38503473 | DOI:10.1136/ard-2024-225534 (Source: Herpes)
Source: Herpes - March 19, 2024 Category: Infectious Diseases Authors: Andreas Kerschbaumer Josef S Smolen Ricardo J O Ferreira Heidi Bertheussen Xenofon Baraliakos Daniel Aletaha Dennis G McGonagle D ésirée van der Heijde Iain B McInnes Bente Appel Esbensen Kevin L Winthrop Wolf-Henning Boehncke Jan W Schoones Laure Gosse Source Type: research
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
CONCLUSION: Switching to a different MoA may provide long-term benefit to patients with RA not achieving treatment goals with their initial therapy, with acceptable safety profiles.TRIAL REGISTRATION: NCT02629159.PMID:38498140 | DOI:10.1007/s40744-024-00658-1 (Source: Herpes)
Source: Herpes - March 18, 2024 Category: Infectious Diseases Authors: Roy Fleischmann Ricardo Blanco Filip Van den Bosch Louis Bessette Yanna Song Sara K Penn Erin McDearmon-Blondell Nasser Khan Kelly Chan Eduardo Mysler Source Type: research
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
CONCLUSION: Switching to a different MoA may provide long-term benefit to patients with RA not achieving treatment goals with their initial therapy, with acceptable safety profiles.TRIAL REGISTRATION: NCT02629159.PMID:38498140 | DOI:10.1007/s40744-024-00658-1 (Source: Herpes)
Source: Herpes - March 18, 2024 Category: Infectious Diseases Authors: Roy Fleischmann Ricardo Blanco Filip Van den Bosch Louis Bessette Yanna Song Sara K Penn Erin McDearmon-Blondell Nasser Khan Kelly Chan Eduardo Mysler Source Type: research
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
ConclusionsEarly treatment response and baseline characteristics, including smoking, psoriasis duration, and obesity, may be associated with longer-term response to biologics.Trial Registration NumbersECLIPSE: NCT03090100, VOYAGE 1: NCT02207231. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 15, 2024 Category: Dermatology Source Type: research
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
Clin Cosmet Investig Dermatol. 2024 Feb 29;17:483-487. doi: 10.2147/CCID.S456817. eCollection 2024.ABSTRACTManaging HS has long posed a significant challenge for dermatologists. Adalimumab stands as the sole biologic drug sanctioned for HS, receiving approval in 2015 as an anti-tumor necrosis factor (TNF)-α drug. Real-life evidence over the years has debated its efficacy, suggesting a success rate hovering around 70%. However, the variability in existing treatments and the chronic-recurrent nature of the condition make its treatment and management exceedingly challenging. Hence, identifying new therapeutic targets for HS ...
Source: Clinical, Cosmetic and Investigational Dermatology - March 13, 2024 Category: Dermatology Authors: Fabrizio Martora Teresa Battista Luca Potestio Antonio Portarapillo Nello Tommasino Matteo Megna Source Type: research
Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
Clin Cosmet Investig Dermatol. 2024 Mar 5;17:547-552. doi: 10.2147/CCID.S454057. eCollection 2024.ABSTRACTSynovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease mainly manifested as skin and osteoarticular lesions. Herein, we describe a female patient with SAPHO syndrome exhibited paradoxical psoriasis and primary palmoplantar pustulosis (PPP) worsened during treatment with adalimumab. We then switched to secukinumab and obtained significant improvement in both skin lesions and osteoarticular pain. These findings suggest that secukinumab might be an appropriate optio...
Source: Clinical, Cosmetic and Investigational Dermatology - March 13, 2024 Category: Dermatology Authors: Danyang Fan Fuqiu Li Zhe Liu Zhanhan Tang Sha Lv Source Type: research
